• 1
    Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 11826.
  • 3
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 46.
  • 4
    Wu JM, Staton CA. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin Drug Discov 2012; 7: 72343.
  • 5
    Sim BK, Fogler WE, Zhou XH et al. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999; 3: 4151.
  • 6
    Zhao X, Mei K, Cai X et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs 2012; 30: 11449.
  • 7
    Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 254250.
  • 8
    Wang JW, Sun Y, Liu YY et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chin) 2005; 8: 28390.
  • 9
    Han B, Xiu Q, Wang H et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 11046.
  • 10
    Casanovas O. Cancer: limitations of therapies exposed. Nature 2012; 484: 446.
  • 11
    Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 22847.
  • 12
    Herbst RS, Hess KR, Tran HT et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792803.
  • 13
    Cavallo T, Sade R, Folkman J, Cotran RS. Tumor angiogenesis. Rapid induction of endothelial mitoses demonstrated by autoradiography. J Cell Biol 1972; 54: 40820.
  • 14
    Keegan A, Hill C, Kumar S, Phillips P, Schor A, Weiss J. Purified tumour angiogenesis factor enhances proliferation of capillary, but not aortic, endothelial cells in vitro. J Cell Sci 1982; 55: 26176.
  • 15
    Duong HT, Erzurum SC, Asosingh K. Pro-angiogenic hematopoietic progenitor cells and endothelial colony-forming cells in pathological angiogenesis of bronchial and pulmonary circulation. Angiogenesis 2011; 14: 41122.
  • 16
    Fürstenberger G, von Moos R, Lucas R et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006; 94: 52431.
  • 17
    Chu TQ, Ding H, Garfield DH et al. Candetermination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non–small-cell lung cancer receiving endostatin and paclitaxel–carboplatin chemotherapy? A retrospective study J Thorac Oncol 2012; 7: 17819.
  • 18
    Li Y, Yang ZG, Chen TW, Yu JQ, Sun JY, Chen HJ. First-pass perfusion imaging of solitary pulmonary nodules with 64-detector row CT: comparison of perfusion parameters of malignant and benign lesions. Br J Radiol 2010; 83: 78590.
  • 19
    Sitartchouk I, Roberts HC, Pereira AM, Bayanati H, Waddell T, Roberts TP. Computed tomography perfusion using first pass methods for lung nodule characterization. Invest Radiol 2008; 43: 34958.
  • 20
    Fournier LS, Oudard S, Thiam R et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010; 256: 5118.
  • 21
    Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 365861.
  • 22
    Ali AM, Ueno T, Tanaka S, Ishiguro H, Abdellah AZ, Toi M. Determining circulating endothelial cells using Cell Search system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer 2011; 47: 226572.
  • 23
    Rowand JL, Martin G, Doyle GV et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007; 71: 10513.
  • 24
    Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 176571.
  • 25
    Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 94757.
  • 26
    Tudorica A, Thomas CR Jr, Huang W. Invited commentary. Radiographics 2010; 30: 7169.
  • 27
    Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer 2012; 106: 11539.
  • 28
    Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS ONE 2011; 6: e19873.
  • 29
    Bernaards C, Hegde P, Chen D et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. J Clin Oncol 2010; 28(Suppl. 15): abstract 10519.
  • 30
    Hunting CB, Noort WA, Zwaginga JJ. Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. Vox Sang 2005; 88: 19.
  • 31
    Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 8248.
  • 32
    Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 396472.
  • 33
    Li H, Raia V, Bertolini F, Price DK, Figg WD. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008; 101: 8848.
  • 34
    Beaudry P, Force J, Naumov GN et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 351422.
  • 35
    Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 264350.
  • 36
    Wang J, Huang C, Wei XY et al. Changes of activated circulating endothelial cells and surviving in patients with non-small cell lung cancer after antiangiogenesis therapy. Chin Med J (Engl) 2008; 121: 233440.
  • 37
    Shaked Y, Henke E, Roodhart JM et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 26373.
  • 38
    Roodhart JM, Langenberg MH, Vermaat JS et al. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010; 12: 8794.
  • 39
    Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 43426.
  • 40
    Lu N, Ling Y, Gao Y et al. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood) 2008; 233: 101320.
  • 41
    Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 37316.
  • 42
    Starlinger P, Brugger P, Reiter C et al. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 2011; 13: 98090.
  • 43
    Bellomi M, Viotti S, Preda L, D'Andrea G, Bonello L, Petralia G. Perfusion CT in solid body-tumours part II. Clinical applications and future development. Radiol Med 2010; 115: 85874.
  • 44
    Eastwood JD, Lev MH, Provenzale JM. Perfusion CT with iodinated contrast material. AJR Am J Roentgenol 2003; 180: 312.
  • 45
    Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therap. Nat Rev Cancer 2008; 8: 592603.
  • 46
    Kawaishi M, Fujiwara Y, Fukui T et al. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2009; 4: 20813.
  • 47
    Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007; 244: 48693.
  • 48
    Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW. Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 2007; 72: 8693.